Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421663 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 439
- Enrollment target
- 20
- Study locations
NCT05421663: Recruiting Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Janssen Research & Development.
NCT05421663 is a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 439 participants, above the 382-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421663, a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 439 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Primary Outcome
Occurrence of any AEs, including dose limiting toxicities (DLTs).
Conditions Studied
Interventions
- BIOLOGICAL Prizloncabtagene autoleucel (Prizlo-Cel)
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Fitzroy
- The Alfred Hospital - Melbourne
- Fiona Stanley Hospital - Murdoch
- Calvary Mater Newcastle Hospital - Waratah
- Rigshospitalet - Copenhagen
- Odense University Hospital - Odense
Tennessee
- Greco Hainesworth Tennessee Oncology Centers for Research - Nashville
- Sarah Cannon Research Institute - Nashville
Texas
- St. David's South Austin Medical Center - Austin
- Texas Transplant Institute - San Antonio
California
- City of Hope - Duarte
Colorado
- Colorado Blood Cancer Institute - Denver
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Kentucky
- University of Kentucky Medical Center - Lexington
New Jersey
- Rutgers Cancer Institute of New Jersey - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2029-03-12 |
| Phase | Phase 1 |
What NCT05421663 shows while recruiting
NCT05421663 is an interventional study that assigns participants to a tested intervention. The registered 439 participants enrollment target is mid-sized for trials with a published cap, above the 382-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (15% higher).
The record links to 3 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Prizloncabtagene autoleucel (Prizlo-Cel) is the first listed.
NCT05421663 names 20 study sites across 13 states, led by Other, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05421663 about?
NCT05421663 is a clinical study titled "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma". This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refract...
What is the current status of trial NCT05421663?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 439 participants. The study started on 2022-08-12. Estimated completion is 2029-03-12.
What conditions does trial NCT05421663 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT05421663?
The interventions under investigation include: Prizloncabtagene autoleucel (Prizlo-Cel) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05421663?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05421663 being conducted?
This trial has 20 study locations across California, Colorado, Iowa, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05421663's enrollment target sits among peer trials
439 11th of 58 higher than 48 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI